Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Strategies for third line therapy

    Project Inform Perspective
    |June 1, 2002
    PubMed
    Summary
    This summary is machine-generated.

    Exploring third-line HIV therapy options is crucial when standard treatments fail. This review details available regimens for patients with resistance to multiple anti-HIV drug classes.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010
    See all related articles

    Area of Science:

    • HIV/AIDS Research
    • Antiretroviral Therapy Strategies

    Background:

    • Limited data exists for third-line antiretroviral therapy (ART) regimens.
    • Third-line therapy is defined for patients with resistance to nucleoside analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors, or after failing two prior regimens.

    Discussion:

    • Tenofovir, a nucleotide analogue, can exhibit NRTI resistance patterns.
    • Despite resistance to multiple drug classes, treatment options remain available.

    Key Insights:

    • Physicians and patients require better guidance for third-line HIV treatment decisions.
    • Understanding resistance patterns is key to selecting effective salvage regimens.

    Outlook:

    • Further research is needed to expand the evidence base for third-line ART.
    • This review aims to provide a comprehensive overview of current third-line regimen choices.